Open AccessEvaluation of the role of erythropoietin and methotrexate in multiple sclerosis
Author(s) -
Sandipan Dasgupta,
Bhaskar Mazumder,
Y Roja Ramani,
Subhra Prakash Bhattacharyya,
Mukesh Kumar Das
Publication year - 2011
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.84955
Subject(s) - medicine , methotrexate , erythropoietin , multiple sclerosis , rheumatoid arthritis , immunology , encephalomyelitis , experimental autoimmune encephalomyelitis
Erythropoietin, originally recognized for its role in erythropoiesis, has been shown to improve neurological outcome after stroke. Low-dose methotrexate is effective against certain inflammatory diseases, such as severe psoriasis and rheumatoid arthritis as well as Crohn's disease. Immunosuppressive effect of methotrexate also reduces the proportion of patients with chronic progressive multiple sclerosis with modest clinical benefits. Combination of erythropoietin and methotrexate can target neuroinflammation along with immunosupression.